Harmony Biosciences Holdings (HRMY) Operating Expenses (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Operating Expenses data on file, last reported at $133.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 38.44% year-over-year to $133.6 million; the trailing twelve-month figure through Mar 2026 stood at $498.7 million (up 28.38% YoY), and the FY2025 full-year result was $461.6 million, up 25.76% from the prior year.
• Operating Expenses declined to $133.6 million in Q1 2026, from $136.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $136.7 million in Q4 2025 to a low of $43.0 million in Q1 2022.
• A 5-year average of $86.2 million and a median of $82.3 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses decreased 22.93% in 2023 and jumped 91.5% in 2024, its largest moves.
• Tracing HRMY's Operating Expenses over 5 years: stood at $53.8 million in 2022, then soared by 58.08% to $85.1 million in 2023, then rose by 7.13% to $91.1 million in 2024, then surged by 49.98% to $136.7 million in 2025, then slipped by 2.26% to $133.6 million in 2026.
• Business Quant data shows HRMY's Operating Expenses at $133.6 million in Q1 2026, $136.7 million in Q4 2025, and $114.3 million in Q3 2025.